

Special Issue

Advances in the Pathogenesis and Treatment of AIDS

Message from the Guest Editor

HIV is a viral infection that leads to AIDS, a condition characterized by a compromised immune system, rendering individuals more susceptible to infections and cancer. Although antiretroviral therapy (ART) has provided a dramatic reduction in HIV-related morbidity and mortality, many issues are still current and deserve timely resolution considering the ambitious targets formulated by the World Health Organization by 2025. Among the challenges that still require effort through both basic and clinical research, we can include: access to healthcare in developing countries with a reduction in AIDS-related mortality, detection of the underground of infections, strategies to eradicate infections on a global scale, optimizations of antiretroviral therapies, determinants of virological failure, implementation of new regimen long-acting injectables, personalization and tailoring of ART, and improvement of the quality of life in people living with HIV (PLWH). The purpose of this Special Issue is to gather both basic and clinical research experiences that can underscore the undeniable progress in the pathogenesis and treatment of AIDS. We welcome both research articles and reviews.

Guest Editor

Dr. Giuseppe Bruno

Infectious Diseases Unit, San Giuseppe Moscati Hospital, Azienda Sanitaria Locale Taranto, 74121 Taranto, Italy

Deadline for manuscript submissions

closed (31 July 2025)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/190192

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).